Deal Watch: GSK Accelerates TCR Collaboration With Adaptimmune
Merger combines troubled Avalanche's resources with Annapurna's brimming pipeline. Janssen sells its BetaLogic stem-cell IP to partner ViaCyte to hasten development of a stem cell therapeutic for diabetes.
You may also be interested in...
Allergan backs out of deal with Adamis for an EpiPen competitor just two months after signing the licensing deal, but before an up-front payment due date kicks in. AbCellera to team with MassBiologics to discover antibodies against drug-resistant Klebsiella infections.
The big biotech enters a collaboration in cancer immunotherapy and inflammation with Xencor, acquires Dutch biotech Dezima, and licenses a c-MET inhibitor to NantWorks. Also, Sun Pharma steps in to buy InSite Vision, which had been targeted by QLT.
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.